MyoKardia, Inc. is pioneering a precision medicine approach to treating genetic heart disease.
By combining leading-edge cardiovascular genetics with recent advances in heart muscle biochemistry, MyoKardia seeks to revolutionize the treatment of cardiomyopathies and make a meaningful difference in the lives of the millions of people suffering from cardiovascular diseases.
News & Events
MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy
MyoKardia CEO Tassos Gianakakos Discusses Company’s Precision Medicine Approach to Cardiovascular Disease on Fox Business News
MyoKardia to Present at the 33rd Annual J.P. Morgan Healthcare Conference